Fairmount Funds Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-283,000	Closed	-$33.8M	–	19
2022 Q4	$33.8M	Hold	283,000	–	–	5.36%	6
2022 Q3	$30.1M	Hold	283,000	–	–	5.28%	6
2022 Q2	$27.6M	Buy	+283,000	New	+$27.6M	6.31%	6